title: Enalapril plus frusemide MAG3 scintigraphy in hypertensive patients with atherosclerosis and moderate renal insufficiency.
abstract: We performed a retrospective study on 26 patients with moderate renal failure (mean GFR = 51 +/- 21 ml min-1 1.73 m-2), hypertension and atherosclerosis. Apart from three patients who had completely normal renal Doppler ultrasonography, all patients underwent renal angiography. Three groups of kidneys with different atherosclerotic renal artery involvement were identified: Group 1, 24 kidneys with no renal artery stenosis (RAS); Group 2, 18 kidneys with mild (> 25% and < 50% diameter) RAS; and Group 3, 10 kidneys with moderate (> 50% diameter) RAS. We used a two-day protocol with frusemide plus enalapril 99Tcm-MAG3 scintigraphy. The mean parenchymal transit time (MPTT), time to the maximum activity (time to peak) of the renal curve (Tmax), residual activity and split renal uptake were evaluated. The measured parameters did not differ before and after enalapril in Group 1 or in Group 2. In Group 3, MPTT and residual activity differed significantly (P < 0.025) before and after enalapril. The Tmax before and after enalapril, MPTT before and after enalapril and residual activity after enalapril differed significantly (P < 0.05) between Groups 1 and 3 and between Groups 2 and 3. Threshold values were obtained to maximize diagnostic accuracy. The Tmax, MPTT and residual activity after enalapril gave satisfactory results, and MPTT performed best with a 75% positive predictive value and a 98% negative predictive value for the diagnosis of renal artery stenosis. We conclude that MPTT, measured after enalapril administration, is a useful parameter to detect renal artery stenosis in patients with hypertension, atherosclerosis and moderate renal insufficiency.
authors.affiliation: Departement de Médecine Nucléaire, CHU Avicenne, Montreuil, France.
authors.forename: M
authors.initials: M
authors.lastname: Caglar
authors.forename: J L
authors.initials: JL
authors.lastname: Moretti
authors.forename: P
authors.initials: P
authors.lastname: Buchet
authors.forename: P
authors.initials: P
authors.lastname: Weinmann
authors.forename: G
authors.initials: G
authors.lastname: Baillet
authors.forename: A
authors.initials: A
authors.lastname: Prigent
authors.forename: J
authors.initials: J
authors.lastname: Laedrich
authors.forename: P
authors.initials: P
authors.lastname: Le Tourmelin
authors.forename: D
authors.initials: D
authors.lastname: Kleinknecht
authors.forename: A
authors.initials: A
authors.lastname: Meyrier
mesh_terms: D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors; D001161:Arteriosclerosis / Q000150:complications / Q000000981:diagnostic imaging*; D004232:Diuretics; D004656:Enalapril; D005665:Furosemide; D005919:Glomerular Filtration Rate; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000000981:diagnostic imaging*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000000981:diagnostic imaging*; D008875:Middle Aged; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012078:Renal Artery Obstruction / Q000150:complications / Q000000981:diagnostic imaging*; D012189:Retrospective Studies; D017263:Technetium Tc 99m Mertiatide
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; D019275:Radiopharmaceuticals; D017263:Technetium Tc 99m Mertiatide; D004656:Enalapril; D005665:Furosemide